In Singapore, one biotech company is changing how we approach cancer treatment. CytoMed Therapeutics, just launched its ANGELICA clinical trial, to fundamentally change how we make cancer treatments available to patients worldwide. Building on the success of CAR T-cell therapy in treating blood cancers, they’re taking things to the next level by tackling a broader range of cancers while making the whole process quicker, easier, and more affordable for patients. “Think of it as training a versatile army of super-soldiers to fight cancer,” explains Peter Choo, Chairman of CytoMed. “Traditional CAR T-cell therapy takes soldiers from the patient’s own body, but these soldiers are often weakened because the patient has already been through multiple rounds of chemotherapy. Instead, we’re recruiting healthy soldiers from disease-free, well donors and equipping them with special targeting systems to hunt down cancer cells.”

Full report : CytoMed, a Singapore Biotech, Revolutionizes Cancer Treatment Using Donor Immune Cells.